Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.
NCT07451561 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74
Last updated 2026-03-05
Summary
Metal phosphides are commonly utilized for safeguarding stored grains due to their desirable characteristics. They have high potency and the ability to combat different pests and produce non-toxic residues in crops .
In countries like Iran, India, and Egypt, metal phosphides are extensively employed in agriculture. Some examples of metal phosphides are aluminum phosphide (ALP), zinc phosphide, magnesium phosphide, and calcium phosphide .
ALP poisoning is a prevalent method for suicide in most of developing countries such as North India, Iran, and Egypt . ALP poisoning is becoming more common in Egypt, and poison control centers are seeing an increase in cases .
ALP which is a potent poison with an oral LD50 of 11.5 mg/kg, is utilized as an insecticide, rodenticide, and fumigant. It is available in the form of tablets, commonly referred to as rice tablets or wheat bills. The rice tablet weighs three grams and contains 56% ALP and 44% aluminum carbonate. When it comes into contact with moisture, it releases one gram of Phosphine (PH3) .
PH3 is rapidly absorbed from the respiratory or gastrointestinal tract to reach the systemic circulation. PH3 is a toxic substance that can cause various harmful effects .
The cause of hypotension in ALP poisoning is thought to be due to the direct toxic effects of phosphine on cardiac myocytes, fluid loss and adrenal gland damage .
PH3 causes collapse of the cardiovascular system, damage to the lungs, and liver dysfunction. Additionally, it can lead to significant imbalances in the body's acid-base and electrolyte levels, resulting in conditions such as metabolic acidosis and hypokalemia As a result, fatalities resulting from metal phosphide exposure are usually caused by a combination of cardiogenic shock, metabolic acidosis, acute pulmonary edema, and liver failure that are difficult to treat There is no known antidote for ALP poisoning, so treatment is only supportive. The success of treatment depends on the severity of the poisoning and how quickly the patient receives medical attention Although no specific antidote for ALP poisoning is available, glucose-insulin-potassium (GIK) infusion precipitating hyperinsulinemia-euglycemia. It is supposed to improve cell carbohydrate metabolism, increases both cardiac inotropy and systemic vascular resistance, and corrects acidosis. As carbohydrates are preferable fuel substrates of the myocardium under stressful conditions. GIK infusion assists in enhanced uptake of carbohydrates and, therefore, results in improved cardiac function
GIK infusion therapy has been advised in the additional management of ischaemia and reperfusion disturbances in ischaemic heart diseases. GIK therapy has been reported to be beneficial in cardiac surgeries.Although the GIK regime, along with supportive care, results in a longer duration of hospital stay, the ultimate outcome of the results is beneficial Adrenal insufficiency may occur as a result of shock; thus, a hydrocortisone infusion is given. Hydrocortisone combats shock; reduces the dose of dopamine; and it additionally checks capillary leakage in the lungs to prevent ARDS Use of hydrocortisone in treatment of shocked patients has a promising outcome as it stabilizes cell membranes, reduces systemic inflammation, and helps manage refractory hypotension Sevelamer (SVLM) is approved by the US Food and Drug Administration for the treatment of hyperphosphatemia in patients with chronic kidney disease or end-stage renal disease (De Santi et al., 2024).
Sevelamer is being "repurposed" as a potential oral antidote for treating aluminum phosphide poisoning. Sevelamer may serve as an effective antidote by its interaction with phosphine gas.
While GIK and Hydrocortisone address the effects of the poison (shock and metabolic collapse), Sevelamer is unique because it may directly target and neutralize the toxic phosphine gas itself
Conditions
- Acute Aluminum Phosphide Poisoned Cases
Interventions
- DRUG
-
Gastric lavage with paraffin oil
with paraffin oil about 6 bottles (3 for lavage and 3 left in the stomach) then Nil Per Os (NPO) for 48 hrs.
- DRUG
-
GIK solution
bolus of 1-3 IU/kg regular insulin together with 0.5-1 gm/kg dextrose followed by an intravenous infusion of 0.2 to 1 IU/kg/hr of regular insulin and a dextrose infusion will be started at 0.5gm/kg/hr. The dextrose infusion rate will be adjusted to maintain blood glucose between 140-180 mg/dL. Potassium will be given at dose of 20-80 meq/L of potassium chloride to maintain serum potassium at 3.5 to 4.5 meq/L. GIK will be administered via a central line
Sponsors & Collaborators
-
Sohag University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 12 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-03-31
- Primary Completion
- 2027-03-31
- Completion
- 2027-03-31
Countries
- Egypt
Study Locations
More Related Trials
-
Leveraging Plasma Concentration Levels to Optimize Extracorporeal Treatment in Acute Diquat Poisoning
NCT06807151 ·Status: COMPLETED
-
Risk Stratification and Heterogeneity for Organ Damage in Acute Diquat Poisoning
NCT06798142 ·Status: ACTIVE_NOT_RECRUITING
-
Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning
NCT02760823 ·Status: UNKNOWN ·Phase: PHASE2
-
A Pilot Study Using Rocuronium to Prevent Intermediate Syndrome After Organophosphorus Insecticide Poisoning
NCT02147054 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Adding Nebulized Salbutamol to Intravenous Atropine and Oxygen in OP Poisoning
NCT02160548 ·Status: COMPLETED ·Phase: PHASE3
-
To Study the Effects of Lipid Emulsion on Hemodynamics in Organophosphate Compound Poisoning
NCT03564574 ·Status: COMPLETED ·Phase: PHASE4
-
Role of Intralipid in Management of Organophosphorus Poisoning
NCT04393103 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Clinical Spectrum and Outcome of Poisoning in Children Admitted to the Pediatric Emergency and Intensive Care Units at Sohag University Hospital
NCT06447584 ·Status: RECRUITING
-
Assessing The Role Of Intravenous Lipid Emulsion As A Life Saving Therapy In Pesticides Toxicity
NCT05006638 ·Status: UNKNOWN ·Phase: PHASE4
-
Physiologic Effects of Steroids in Cardiac Arrest
NCT02790788 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
NCT04848779 ·Status: ACTIVE_NOT_RECRUITING
-
Paraoxonase-1 Pseudo Cholinesterase Organophosphate Toxicity Enzyme in Prediction the Severity and Outcome of Acute Organophosphate Poisoning and Its Correlation With Pseudo Cholinesterase Enzyme Level.
NCT06108557 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Fresh Frozen Plasma Transfusion in Acute Organophosphate Poisoning
NCT06256796 ·Status: RECRUITING ·Phase: NA
-
Is the WHO Recommended Dose of Pralidoxime Effective in the Treatment of Organophosphorus Poisoning?
NCT02040350 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Enteral Versus Intravenous Potassium Supplementation
NCT02015962 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of Glucose-Insulin-Potassium Infusion in Patients Undergoing Cardiac Surgery
NCT00788242 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa
NCT03019406 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Stepwise Enteral Nutritional Algorithm and Patient Outcomes in Pediatric Intensive Care Units
NCT07307027 ·Status: RECRUITING ·Phase: NA
-
Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients
NCT00512811 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Know the Efficacy of Higher Doses of Pralidoxime in Patients of Organophpsphorus Poisoning.
NCT00333944 ·Status: COMPLETED ·Phase: NA
-
Acute Effects of Propylene Glycol/Glycerol Intake on Blood Parameters
NCT03404011 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Mechanisms of GLN Dipeptide in the SICU
NCT00248638 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of "in UTERO" Exposure to Glucocorticoids
NCT01367106 ·Status: UNKNOWN ·Phase: NA
-
Corticosteroid Treatment in the Acute Phase of Caustic Ingestion Management
NCT03760354 ·Status: UNKNOWN ·Phase: PHASE2
-
Outcome of Moderate Severity in OPC Poisoning Patients When Treated With Pralidoxime
NCT06111352 ·Status: COMPLETED ·Phase: PHASE2